The FDA set a PDUFA target action date of March 31, 2027, for tabelecleucel in relapsed or refractory EBV-positive post-transplant lymphoproliferative disease.
|Videos|May 31, 2011
Reynaldo Garcia Explains the BCR-ABL Study
Author(s)Reynaldo Garcia, RN, OCN
Reynaldo Garcia from the UNC Lineberger Comprehensive Cancer Center Explains the BCR-ABL Study
Advertisement
Reynaldo Garcia, RN, OCN® from the University of North Carolina Lineberger Comprehensive Cancer Center Explains the BCR-ABL Study
Advertisement
Related to this article
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
Novel NAMPT inhibitors may circumvent the limited tolerability of previously studied agents and improve treatment outcomes in AML and MDS.
Epcoritamab plus R-CHOP reduced the risk of progression or death by 51% vs R-CHOP alone in newly diagnosed DLBCL.
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
Advertisement
Advertisement
Trending on OncLive
1
Stay Ahead of ESMO 2026: See What Lung Cancer Experts Are Prioritizing
2
CHMP Recommends Approval of Daraxonrasib for Previously Treated Metastatic Pancreatic Cancer
3
VOLGA, DASL-HiCaP Data Highlight Key Genitourinary Cancer Presentations Arriving at ESMO 2026
4
Refined ADC Development Helps Weigh Biomarker-Based Decisions and Treatment Sequencing in Gynecologic Cancers
5